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Abstract
Background: Pulmonary hypertension (PH) occurs frequently and results in functional limitation in advanced COPD. Data
regarding the functional consequence of PH in less severe COPD are limited. Whether echocardiographic evidence of right
sided heart pathology is associated with functional outcomes in patients with non-severe COPD is unknown.
Methods: We evaluated pulmonary function, six minute walk distance, and echocardiography in 74 consecutive patients
with non-severe COPD. We performed multivariable linear regression to evaluate the association between right heart
echocardiographic parameters and six minute walk distance adjusting for lung function, age, sex, race, and BMI.
Main Results: The mean six minute walk distance was 3246106 meters. All subjects had preserved left ventricular (LV)
systolic function (LV ejection fraction 62.3%66.1%). 54.1% had evidence of some degree of diastolic dysfunction. 17.6% of
subjects had evidence of right ventricular enlargement and 36.5% had right atrial enlargement. In univariate analysis RV wall
thickness (b=268.6; p=0.002), log right atrial area (b=2297.9; p=0.004), LV mass index (b=21.3; p=0.03), E/E’ ratio
(b=25.5; p=0.02), and degree of diastolic dysfunction (b=242.8; p=0.006) were associated with six minute walk distance.
After adjustment for co-variables, the associations between right atrial area (log right atrial area b=2349.8; p=0.003) and
right ventricular wall thickness (b=243.8; p=0.04) with lower six minute walk distance remained significant independent of
forced expiratory volume in one second (FEV1). LV mass index, E/E’ ratio, and degree of diastolic dysfunction were not
independent predictors of six minute walk distance.
Conclusion: In patients with non-severe COPD right sided cardiac structural changes are associated with lower six minute
walk distance independent of lung function. These findings may indicate that echocardiographic evidence of pulmonary
hypertension is present in patients with non-severe COPD and has important functional consequences.
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Introduction
Chronic obstructive pulmonary disease (COPD) recently
surpassed cerebrovascular disease to become the third leading
cause of death in the United States, and is the only leading cause of
death that is increasing in prevalence [1]. COPD is a complex
disease that has effects not only on the lungs but multiple organ
systems throughout the body [2,3,4]. Current therapy for patients
with COPD, including bronchodilators and inhaled corticoste-
roids, do not modify disease progression [5]. The next innovation
in the management of patients with COPD will be identifying and
grouping key elements of the clinical presentation into distinct
phenotypes to add useful prognostic information and guide more
targeted therapy. Identifying these phenotypes early in the course
of the disease may allow for effective intervention that will alter the
natural history of the disease [6,7].
Pulmonary hypertension (PH) occurs frequently in patients with
advanced COPD and has been associated with decreased exercise
capacity and increased mortality independent of degree of
impairment in lung function [8,9]. Given the unique contribution
to outcome, PH in COPD appears to represent a distinct
phenotype. PH is defined hemodynamically by right heart
catheterization [10]. Due to the invasive nature of cardiac
catheterization, most prior descriptions of PH in COPD have
studied patients with advanced COPD awaiting lung transplan-
tation, in whom cardiac catheterization was clinically indicated
[11,12]. Patients with mild to moderate lung disease do not
typically undergo right heart catheterization and as a result PH
and its potential functional impact are poorly described in this
population. There is, however, evidence that pathologic changes
to the pulmonary vasculature consistent with pulmonary hyper-
tension occur at all stages of COPD severity [13].
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following the progression of patients with PH [14,15]. Although
limitations exist in using echocardiography to definitively diagnose
PH, it is an indispensible tool in evaluating and following the
structural and functional changes of the right heart related to
pulmonary hypertension. We investigated if structural changes of
the right heart described in patients with pulmonary hypertension
are associated with worse exercise capacity in patients with mild,
moderate, and moderately severe COPD.
Methods
We reviewed 74 consecutive patients with clinically indicated
echocardiograms and pulmonary function data seen in the
Northwestern Asthma and COPD program between July 1,
2006 and April 1, 2010. The Northwestern University Institutional
Review Board approved the study and granted a waiver of
informed consent. Data collected included general demographic
information, six minute walk distance, Modified Medical Research
Council (MMRC) dyspnea scores, BODE (Body mass index,
degree of Obstruction (FEV1), Dyspnea score (MMRC scale),
Exercise capacity (six minute walk distance)) index, echocardio-
graphic parameters, and full pulmonary function testing.
Pulmonary function testing including spirometry, lung volumes,
and diffusion capacity for carbon monoxide (DLCO) was
performed in the hospital pulmonary function laboratory by
trained technicians according to ATS-ERS standards and guide-
lines [16,17,18]. We selected patients with mild, moderate, and
moderately severe COPD based on guidelines of the American
Thoracic Society: mild was defined as FEV1/FVC ratio ,0.7 and
FEV1 percent predicted .70%, moderate was defined as FEV1/
FVC ratio ,0.7 and FEV1 percent predicted 60–69%, and
moderately severe was defined as FEV1/FVC ratio ,0.7 and
FEV1 percent predicted 50–59% [19]. Lung volumes were
measured using body plethysmography in 95% (70/74) of patients,
the remaining 5% were measured by nitrogen washout.
Six minute walk testing was performed in the Northwestern
Asthma and COPD clinic by trained technicians according to
ATS guidelines [20].
Echocardiograms were performed in the clinical echocardiog-
raphy laboratory using either Philips (ie33) or GE (Vivid7)
echocardiography machines. All studies were analyzed and mea-
sured using a systematic protocol by a single cardiologist blinded to
all other data. Echocardiographic data collected for analysis
included: left ventricular (LV) end diastolic dimension, biplane LV
end-diastolic volume, biplane LV end-systolic volume, LV mass,
LV ejection fraction, cardiac output, left atrial volume, right
ventricular (RV) basilar diameter, RV longitudinal dimension, RV
end diastolic area, RV wall thickness, RV outflow track diameter,
right atrial area, early mitral inflow velocity (E), late mitral inflow
velocity (A), early septal diastolic longitudinal velocity (E’), diastolic
function grade, peak tricuspid regurgitation (TR) velocity,
pulmonary artery systolic pressure, tricuspid annular plane systolic
excursion (TAPSE), and RV fractional area change [21,22].
All echocardiographic parameters were measured and calculat-
ed according to previously published guidelines [21]. Diastolic
function was graded by analyzing mitral inflow patterns, tissue
Doppler E’ velocity, and echocardiographic estimation of LV
filling pressure (E/E’ ratio) using a previously published method
[23]. Patients were categorized as indeterminate diastolic function
if they could not be classified based on the aforementioned
diastolic function parameters.
Data are presented as mean 6 standard deviation or frequency
and percent. Univariable and multivariable analyses were per-
formed to evaluate whether echocardiogram parameters or lung
function variables predicted six minute walk distance. Comparison
of means was done via Student’s t tests. Multiple means were
compared using analysis of variance (ANOVA) with Bonferroni
adjustment for multiple comparisons. The relationships between
given parameters and the 6MWD were assessed by univariable
and multivariable linear regression. Co-variables included in
statistical models were pre-specified based on a known or
hypothesized association with exercise tolerance in COPD. Age,
sex, height and weight were specifically included as co-variables
given their direct impact on six minute walk distance [24].
Statistical analysis was completed using Graphpad software (Prism
4, San Diego, California) and STATA software (STATA 10,
College Station, Texas).
Results
Subjects were predominantly Caucasian (72.2%) and had a
mean age of 72611 years and a body mass index of 27.866.0 kg/
m
2. There was no difference in sex, age, or race across levels of
COPD severity. The total lung capacity was within normal limits
(TLC% predicted; 100614.7%) but the residual volume was
elevated (RV %predicted; 125.9632.7%). The diffusion capacity
for carbon monoxide (DLCO % predicted) was moderately
reduced (55.8618.2%), however oxygen saturation at rest was
normal (96.062.7%). The mean six minute walk distance was
3246106 meters. The mean six minute walk distance decreased
with worsening lung function (mild; 3606109 m, moderate;
333695 m, moderately severe 2886108 m, p=0.06) but did
not meet statistical significance. The mean MMRC dyspnea score
was 1.761.1, and mean BODE index was 2.462.1. Both MMRC
(mild; 1.261.3, moderate; 1.860.8, moderately severe; 2.061.2,
p=0.12) and BODE (mild; 1.662.3, moderate; 2.261.7, mode-
rately severe; 3.362.3, p=0.04) increased with worsening lung
function but only BODE was statistically significant. (Table 1)
Full assessment of right heart dimensions was available in all 74
subjects. The mean right ventricular basilar diameter (3.760.5 cm),
right ventricular longitudinal dimension (7.760.9 cm) and right
ventricular end diastolic area (23.764.5 cm
2) were within normal
limits. However, approximately 17.6% of subjects had evidence of
right ventricular enlargement [21]. The mean right atrial area was
at the upper limit of normal (17.865.1 cm
2) with 36.5% of subjects
demonstrating evidence of right atrial enlargement [22]. Right
ventricular wall thickness measurements were available in 61
subjects. The mean wall thickness was 4.860.6 mm, with appro-
ximately 16.4% of subjects demonstrating evidence of right
ventricular hypertrophy. The right ventricular outflow tract was
noted to be dilated in both the proximal (3.560.4 cm) and distal
(3.460.4 cm) diameters. The mean TR jet velocity (3.060.6 m/s)
and the pulmonary artery systolic pressure (44.1616.1 mmHg)
were both elevated but measurements were available in only 46
subjects. Right ventricular function as assessed by both TAPSE
(2.160.5 cm) and right ventricular fractional area change
(47.2%66.3%) was normal. There were no differences in right
heart structure parameters, pressure estimates, or right ventricular
function when compared across degrees of COPD severity.
(Table 2)
To better understand the etiology of right heart changes in this
patient population a full assessment of left ventricular systolic and
diastolic function was obtained. Overall, patients had preserved LV
systolic function (LV ejection fraction 62.3%66.1%) and preserved
cardiac output (as calculated by echocardiogram; 4.762.5 L/min).
The left ventricular end systolic (13.963.8 mL/m
2) and end
diastolic (36.767.1 mL/m
2) volume indices were within normal
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(74.1619.9 g/m
2) and females (68.2620.7 g/m
2). The left atrial
volume indices were at the upper limits of normal for both males
(29.4613.1 mL/m
2) and females (27.6610.9 mL/m
2). There was
no clinically significantdifferenceineitherLVstructural parameters
or LV function when compared across degrees of COPD severity.
(Table 3) Diastolic dysfunction was present in a large percentage of
patients: 15 (20.3%) had normal diastolic function, 40 (54.1%) had
either mild (9 (12.2%)), moderate (30 (40.5%)), or severe (1 (1.4%))
diastolic dysfunction. The remaining 19 (25.7%) patients were
Table 1. Patient Characteristics.
Variable Total Mild Moderate Moderately Severe p value
N 7 41 93 02 5
Gender (male) 54.1% 63.2% 46.7% 56.0% 0.5
Age 72611 72611 72612 73610 0.9
Body Mass Index (kg/m
2) 27.866.0 27.864.6 28.567.2 27.065.6 0.7
Race; % (n) 0.4
White 72.2 (52) 79.0 (15) 73.3 (22) 65.2 (15)
Black 20.8 (15) 15.8 (3) 16.7 (5) 30.4 (7)
Hispanic 1.4 (1) 5.3 (1) – –
Asian 5.6 (4) – 10.0 (3) 4.4 (1)
Lung Function:
FVC (%) 76.6613.1 91.1613.7 75.667.7 66.866.7 ,0.0001
FEV1 (%) 64.8611.7 80.6610.4 63.762.6 54.162.8 ,0.0001
FEV1/FVC ratio 0.6260.05 0.6460.04 0.6360.05 0.6060.05 0.01
TLC (%) 100.3614.7 106.2612.3 100.4616.1 96.1613.5 0.09
FRC (%) 112.9625.1 109.4620.2 116.4627.4 110.6625.4 0.6
RV (%) 125.9632.7 118.2628.4 129.2636.6 127.3630.8 0.5
DLCO (%) 55.8618.2 63.9620.6 59.3617.8 45.6612.0 0.002
O2 Saturation (%) 96.062.7 96.561.1 96.361.9 95.364.0 0.3
Functional Test:
6MWD (m) 3246106 3606109 333695 2886108 0.06
MMRC score 1.761.1 1.261.3 1.860.8 2.061.2 0.12
BODE index 2.462.1 1.662.3 2.261.7 3.362.3 0.04
FVC; forced vital capacity, FEV1; forced expiratory volume in 1 second, ratio; FEV1/FVC ratio, TLC; total lung capacity, FRC; functional residual capacity, RV; residual
volume, DLCO; diffusing capacity of carbon monoxide, 6MWD; six minute walk distance, MMRC; modified medical research council, BODE; Body mass index, degree of
Obstruction (FEV1), Dyspnea score (MMRC scale), Exercise capacity (six minute walk distance).
doi:10.1371/journal.pone.0029069.t001
Table 2. Right Heart Parameters by COPD Severity.
Parameter
Total
(n=74)
Mild
(n=19)
Moderate
(n=30)
Moderately Severe
(n=25) p value*
RV basilar diameter (cm) 3.760.5 3.560.4 3.860.5 3.860.6 0.1
RV longitudinal dimension (cm) 7.760.9 7.860.9 7.761.0 7.660.9 0.6
RV end diastolic area (cm
2) 23.764.5 22.463.9 23.764.2 24.665.3 0.3
RV wall thickness (mm) 4.860.6 4.660.5 4.860.5 4.960.8 0.3
RV outflow track (distal) (cm) 3.460.4 3.460.4 3.560.4 3.460.4 0.6
RV outflow track (proximal)(cm) 3.560.4 3.460.4 3.560.5 3.560.4 0.8
Right Atrial Area (cm
2) 17.865.1 16.162.7 17.865.0 19.166.2 0.14
TR peak jet velocity (m/s) 3.060.6 3.060.6 3.060.6 3.160.6 0.7
PASP (mmHg) 44.1616.1 42.2616.3 42.8615.1 46.7617.6 0.7
TAPSE (cm) 2.160.5 2.260.4 2.160.5 2.160.5 0.6
RV fractional area change (%) 47.266.3 47.365.5 47.165.4 47.467.9 0.9
RV; right ventricular, TR; tricuspid regurgitant jet peak velocity, PASP; pulmonary artery systolic pressure, TAPSE; tricuspid annular plane systolic excursion.
*ANOVA comparing mild, moderate, moderately severe.
doi:10.1371/journal.pone.0029069.t002
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conflicting diastolic function data. RV structural changes were
noted to be present in the sub-group of patients with normal
diastolic function. Approximately 6.7% (1/15) were noted to have
RV enlargement with RV end diastolic area of greater than 29 cm
2
and 33.3% (5/15) had right atrial enlargement with right atrial area
greater than 18 cm
2. The RV wall thickness was within normal
limits in all patients with normal diastolic function. The degree of
diastolic dysfunction was not associated with extent of COPD
severity. (Table 3) There was no difference between patients with
normal, abnormal (mild, moderate, and severe), or indeterminate
diastolic function based on gender, age, body mass index or race.
Likewise, lung function and oxygenation did not differ across the
diastolic function groups. (Table 4)
The RV echo parameters correlated with estimated pulmonary
artery systolic pressure. RV wall thickness (r=0.6, p=0.0002) and
RV basilar diameter (r=0.4, p=0.01) both correlated with
pulmonary artery systolic pressure. The right atrial area (r=0.3,
p=0.06) and RV end diastolic area (r=0.3, p=0.07) both trended
toward an association but did not reach statistical significance.
Markers of LV diastolic function did not correlate with RV
parameters as strongly as PASP: E/A ratio was not correlated with
RV end diastolic area (r=0.003, p=0.9), right atrial area (r=0.2,
p=0.1) or RV wall thickness (r=0.2, p=0.2). E/E’ ratio likewise
showed no correlation with RV end diastolic area (r=0.007,
p=0.9) or right atrial area (r=0.2, p=0.4) but did correlate with
RV wall thickness (r=0.3, p=0.045). (Figure 1)
An evaluation of the association between cardiac function and
structural changes on echocardiogram and six minute walk
distance independent of lung function impairment was performed
using multivariable linear regression. Significant correlations were
noted between the six minute walk distance and both right atrial
area (r=20.4, p=0.002) and right ventricular wall thickness
(r=20.4, p=0.002). (Figure 2) In univariable analysis a 1 mm
change in right ventricular wall thickness was associated with a
68.6 meter decline in the six minute walk distance (b=268.6 m;
p,0.002). The log right atrial area (b=2297.9 m; p=0.004), TR
peak jet velocity (b=20.56 m; p=0.04), pulmonary artery
systolic pressure (b=22.0 m; p=0.04), LV mass index
(b=21.3 m; p=0.03), E/E’ ratio (b=25.5 m; p,0.01) and
degree of diastolic dysfunction (b=242.8 m; p=0.006) were also
inversely associated with six minute walk distance. FEV1
(b=77.1 m; p,0.001) was associated with six minute walk
distance. No association was noted between other right and left
heart parameters, and six minute walk distance. (Table 5)I n
multivariable analysis a 1 mm change in right ventricular wall
thickness was associated with a 43.8 meter decline in the six
minute walk distance (b=243.8 m; p=0.04). This association
was independent of lung function (FEV1), age, sex, race and BMI.
Right atrial area (logRAA; b=2349.8 m; p=0.003) was also
associated with six minute walk distance independent of lung
function, age, sex, race and BMI. TR peak jet velocity
(b=20.26 m; p=0.3), PASP (b=21.0 m; p=0.3), LV mass
index (b=20.75 m; p=0.2), E/E’ ratio (b=22.6 m; p=0.3) and
the degree of diastolic dysfunction (b=230.1 m; p=0.06), were
not independent predictors of six minute walk distance (Table 5).
No association was seen between the echocardiogram param-
eters and MMRC dyspnea score or the integrative BODE index
(data not shown).
Discussion
We report our experience with cardiac structural changes and
their association with patient- centered outcomes in 74 consecutive
patients with mild, moderate, or moderately severe COPD. In this
cohort of patients without severely impaired lung function we
demonstrated that structural changes of the right heart are
associated with a decrement in six minute walk distance. This
association was independent of the severity of COPD as measured
by FEV1 as well as age, sex, race and body mass index. We did not
Table 3. Left Heart Parameters by COPD Severity.
Parameter
Total
(n=74)
Mild
(n=19)
Moderate
(n=30)
Moderately Severe
(n=25) p value*
LV ejection fraction (%) 62.366.1 62.966.1 60.064.6 64.565.9 0.01
Cardiac Output (L/min) 4.762.5 4.962.1 4.062.5 5.662.6 0.06
LV end systolic volume index (mL/m
2) 13.963.8 13.763.2 15.264.2 12.463.1 0.01
LV end diastolic volume index (mL/m
2) 36.767.1 36.864.6 38.169.2 34.865.3 0.2
LV mass index (g/m
2):
Male 74.1619.9 72.2618.7 75.7617.4 74.0624.1 0.9
Female 68.2620.7 71.9627.5 70.1621.4 62.9615.0 0.5
LA volume index (mL/m
2):
Male 29.4613.1 27.2611.5 31.2614.0 29.5614.2 0.7
Female 27.6610.9 26.365.4 31.8614.0 22.464.8 0.08
Diastolic Function, n (%) 0.3
Normal 15 (20.3) 5 (26.3) 8 (26.7) 2 (8.0)
Mild 9 (12.2) 2 (10.5) 2 (6.7) 5 (20.0)
Moderate 30 (40.5) 8 (42.1) 9 (30.0) 13 (52.0)
Severe 1 (1.4) 0 (0) 1 (3.3) 0 (0)
Indeterminate 19 (25.7) 4 (21.1) 10 (33.3) 5 (20.0)
LV; left ventricular, LA; left atrial.
*ANOVA comparing mild, moderate, moderately severe.
doi:10.1371/journal.pone.0029069.t003
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ventricular function as assessed by TAPSE or left ventricular
systolic or diastolic function. This is the first report to our
knowledge of right heart structural changes suggestive of
pulmonary hypertension in patients with non-severe COPD being
linked to a patient-centered functional endpoint. This report is
consistent with our findings that pulmonary hypertension of any
cause has important functional consequences in patients with
advanced COPD, but extends this finding to patients with less
severe disease [25].
Pulmonary hypertension is a well described comorbidity in
advanced COPD. In a study of close to 5000 patients with
advanced COPD awaiting lung transplant, using the standard
definition for pulmonary arterial hypertension (WHO Group 1
PAH, [10]) the frequency of PH related to COPD was found to be
30.4% with an additional 17.2% of patients having PH associated
with elevated left heart filling pressures or pulmonary venous
hypertension. The mean pulmonary artery pressure was found to
be an independent predictor of a lower six minute walk distance
and was associated with an increased risk of death while awaiting
transplant [8]. This highlights the frequency and functional impact
of pulmonary vascular abnormalities in patients with advanced
lung disease. The prevalence and impact of pulmonary vascular
abnormalities in patients with non-severe COPD is unknown.
Pulmonary hypertension is defined hemodynamically by right
heart catheterization and therefore in patients with non-severe
COPD who are typically not subjected to the risks of catheter-
ization pulmonary hypertension is not well described. Higham et
al. evaluated 73 consecutive COPD patients in an outpatient
setting with echocardiographic estimates of pulmonary artery
pressures and found PH to be present in 25% of patients with mild
COPD and 43% of those with moderate COPD [26]. Although
limitations exist in using echocardiography to definitively diagnose
PH, this tool plays an important role in screening for and following
the progression of patients with all forms of PH [14,15]. The utility
of echocardiography has been particularly questioned in patients
with COPD as air trapping and lung hyperinflation may make
attaining adequate ultrasound windows difficult. In our cohort of
patients with less severe lung disease there was no significant
hyperinflation and only mild air trapping, and high quality RV
structural data were obtained in all 74 patients. Therefore,
utilizing non-invasive echocardiogram to explore the importance
of the effect of pulmonary vascular changes on the right heart in
less severe lung disease is feasible in this population.
We found that right ventricular wall thickness and right atrial
area were associated with lower six minute walk distance
independent of lung function. Both right ventricular wall thickness
and right atrial area play an important prognostic role in various
forms of pulmonary hypertension [27,28,29]. Enlargement of the
right atrium is an independent predictor of adverse outcomes in
patients with idiopathic pulmonary arterial hypertension [27]. In a
separate study increased RV wall thickness was associated with a
decreased risk of death in IPAH patients with a dilated right
ventricle. Interestingly, this study also demonstrated that the mean
pulmonary artery pressure was the only independent predictor of
RV wall thickness [29]. In our cohort we found a correlation
between the estimated pulmonary artery systolic pressure on
echocardiogram and the right ventricular end diastolic area, right
atrial area and right ventricular wall thickness. This finding
suggests that an elevation in pulmonary artery pressures may play
a role in the structural changes described in the right heart of
COPD patients. Furthermore, both enlargement of the right
atrium and RV hypertrophy have been postulated to be an early
indicator of RV dysfunction related to pulmonary hypertension in
an at-risk patient population [28]. Interestingly, we did not see an
association between either the right ventricular fractional area
change or TAPSE (a marker of RV longitudinal systolic function)
and six minute walk distance suggesting that perhaps structural
changes of the right heart related to pulmonary hypertension may
precede functional changes. Although right atrial enlargement and
Table 4. Comparison of Diastolic Function.
Parameter
Normal Diastolic Function
(n=14)
Abnormal Diastolic Function
(n=40)
Indeterminate Diastolic Function
(n=19) p value
Gender (male) 60.0% 50.0% 57.9% 0.7
Age 69612 72611 74611 0.3
BMI 25.762.7 27.966.1 29.467.2 0.2
Race; (%) 0.1
Caucasian 12 (80.0) 24 (61.5) 16 (88.9)
Black 1 (6.7) 12 (30.8) 2 (11.1)
Hispanic 0 (0) 1 (2.6) 0 (0)
Asian 2 (13.3) 2 (5.1) 0 (0)
Lung Function
FVC (% predicted) 81.8612.7 75.2613.4 75.5612.7 0.2
FEV1 (% predicted) 66.168.9 63.7612.6 66.1611.8 0.7
FEV1/FVC ratio 0.6060.05 0.6360.05 0.6460.05 0.2
TLC (% predicted) 102.9614.3 100.0615.5 99.2613.7 0.7
RV (% predicted) 120.6633.4 129.3636.9 122.8622.3 0.6
DLCO (% predicted) 58.8619.3 53.7618.3 57.8617.7 0.6
O2 saturation (%) 96629 6 639 6 620 . 9
BMI; body mass index, FVC; forced vital capacity, FEV1; forced expiratory volume in one second, Ratio; FEV1/FVC ratio, TLC; total lung capacity, RV; residual volume,
DLCO; diffusion capacity of carbon monoxide, O2; oxygen.
doi:10.1371/journal.pone.0029069.t004
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with mild and moderate COPD their association with patient-
centered functional endpoints have not been explored [30].
The subjects in this study had preserved left ventricular systolic
function but, a large percentage (56.3%) exhibited some degree of
diastolic dysfunction. Although it is clear that the right heart
structural changes seen in this study are independent of LV systolic
function, without right heart catheterization it is difficult to
differentiate if the changes are related to LV diastolic dysfunction
or primary pulmonary vascular disease. It is interesting to note
that structural changes of the right heart were present in the subset
of patients with both normal left ventricular systolic and diastolic
function. Unfortunately, the total number of observations (n=15)
is too small to draw conclusions related to their impact on
outcomes in this subset of subjects. In advanced COPD the
functional impact of pulmonary hypertension appears to be
independent of the distinction between PH related to pulmonary
vascular disease and PH related to diastolic heart failure. The
mean pulmonary artery pressure has been shown to be associated
with a lower six minute walk distance independent of the left heart
filling pressures which likely drive pulmonary hypertension related
to diastolic heart failure. Furthermore, both primary pulmonary
vascular disease and pulmonary venous hypertension related to
diastolic heart dysfunction impacted survival of patients with
COPD on the lung transplant list compared to those with normal
hemodynamics [25]. However, we know that the therapeutic
Figure 1. The correlation between right ventricular echocardiographic parameters and pulmonary artery systolic pressure
estimates. Panel 1A: The correlation between pulmonary artery systolic pressure (mmHg) and right ventricular wall thickness (cm). Panel 1B: The
correlation between pulmonary artery systolic pressure (mmHg) and right ventricular basilar diameter (cm). Panel 1C: The correlation between
pulmonary artery systolic pressure (mmHg) and right atrial area (cm
2). Panel 1D: The correlation between pulmonary artery systolic pressure (mmHg)
and right ventricular end diastolic area (cm
2).
doi:10.1371/journal.pone.0029069.g001
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hypertension (WHO group 1) and pulmonary venous hypertension
(WHO group 2) are important. Trials looking at PH specific
therapies in COPD have generally been negative perhaps in part
related to the heterogeneity of PH related to COPD. Therefore,
although the mortality and functional impact of PH in COPD may
be independent of the type of PH, the distinction may be very
important when considering therapies to address PH in COPD
whether they be further trials of pulmonary vasodilators or other
novel interventions.
There are a number of limitations to our study. Since
echocardiography was used instead of cardiac catheterization it
is not possible to clearly distinguish whether these patients had PH
related primarily to pulmonary vascular changes or PH related to
left heart disease such as left ventricular diastolic dysfunction.
However, the association between right heart structure and six
minute walk distance remained independent of LV systolic and
diastolic dysfunction. These multivariable regression analyses
suggest that right heart structural changes, above and beyond
that due to left heart disease may be playing a role in limiting
exercise capacity in non-severe COPD. Furthermore, previous
data have shown that although the distinction between pulmonary
arterial and pulmonary venous hypertension is likely important
when making therapeutic decisions, the functional implications of
PH in COPD may be independent of the underlying cause of PH
[8,31]. Nevertheless, to best characterize these patients a right
heart catheterization would be optimal. The reliance on resting
echocardiogram to predict exercise tolerance may also limit our
findings. Isolated exercise induced PH is common in COPD. One
study that prospectively followed 131 subjects with moderate to
severe COPD found that 58% (76/131) of subjects had exercise
induced PH with normal resting hemodynamics. The presence of
isolated exercise induced PH was a predictor of developing resting
PH in the 6 year follow up [32]. Therefore, relying only on a
resting echocardiogram may underestimate the presence of
pulmonary hypertension. We chose to focus on structural changes
Table 5. Association Between Echocardiogram Parameters
and Six Minute Walk Distance.
Univariate Model Multivariate Model
*
Echo Parameter b p value b p value
RV basilar diameter (cm) 244.2 0.06 – –
RV longitudinal dimension (cm) 4.8 0.7 – –
RV end diastolic area (cm
2) 21.7 0.5 – –
RV wall thickness (mm) 268.6 0.002 243.8 0.04
RV outflow track (distal) (cm) 242.2 0.2 – –
RV outflow track (proximal)(cm) 235.8 0.2 – –
log Right Atrial Area (cm
2) 2297.9 0.004 2349.8 0.003
TR peak jet velocity (m/s) 20.56 0.04 20.26 0.3
PASP (mmHg) 22.0 0.04 21.0 0.3
TAPSE (cm) 21.5 0.4 – –
RV fractional area change (%) 308.8 0.12 – –
LV ejection fraction (%) 35.6 0.9 – –
Cardiac Output (L/min) 0.001 0.8 – –
LV end systolic volume index
(mL/m
2)
2.3 0.5 – –
LV end diastolic volume index
(mL/m
2)
2.2 0.2 – –
LV mass index (g/m
2) 21.3 0.03 20.75 0.2
LA volume index (mL/m
2) 21.9 0.06 – –
E/A ratio 26.0 0.8 – –
E/E’ ratio 25.5 0.02 22.6 0.3
Diastolic Function 242.8 0.006 230.1 0.06
*Covariates: FEV1, Age, Sex, Body Mass Index (BMI), RaceRV; right ventricular,
TR; tricuspid regurgitant, PASP; pulmonary artery systolic pressure, TAPSE;
tricuspid annular plane systolic excursion, LV; left ventricular.
doi:10.1371/journal.pone.0029069.t005
Figure 2. The correlation between right ventricular echocardiographic parameters and six minute walk distance. Panel 2A: The
correlation between right atrial area (cm
2) and six minute walk distance (meters); (r=20.4, p=0.002). Panel 2B: The correlation between right
ventricular wall thickness (cm) and six minute walk distance (meters); (r=20.4, p=0.002).
doi:10.1371/journal.pone.0029069.g002
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traditional pressure estimations based on tricuspid regurgitant jet
velocity which may help to capture more of the dynamic changes
in pulmonary pressures over time. Some assessment of exercise
induced cardiac changes, however, would add interesting
information to further define PH in non-severe COPD.
In conclusion, we demonstrated that in subjects with non-severe
COPD right heart structural changes are associated with reduced
six minute walk distance. Early identification of right heart
structural changes in COPD may result in identification of a
specific COPD phenotype which is associated with reduced
exercise capacity. This is consistent with prior reports of PH in
advanced COPD having distinct prognostic and functional
implications. Identification of cardiac structural changes in
patients with COPD that are associated with patient centered
outcomes may lead to novel therapeutic targets to impact a specific
disease phenotype.
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